As per Biocon, the US health regulator has issued complete response letter (CRL) for proposed biosimilar Pegfilgrastim, which is to be used in treatment for cancer.

This product is a part of the biosimilars portfolio being jointly developed by Biocon and Mylan .

Biocon in a regulatory filing stated,”The US Food and Drug Administration has issued a complete response letter (CRL) for Mylan’s Biologics License Application(BLA) for MYL-1401H, a proposed biosimilar pegfilgrastim.”

Further it said that, it is not expecting  the CRL to impact the commercial launch timing of biosimilar Pegfilgrastim in the US.

Read EquityPandit’s Technical Analysis on Nifty Pharma